Publication | Open Access

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

MedicineRandomised Phase 3Metronomic TherapyTh Cr-406/sarc021Evofosfamide Versus DoxorubicinPathologyCancer TreatmentOncologyRadiation OncologyMolecular Oncology